Supporting European Science

We mobilise philanthropic capital and accelerate important medical research.

What Scientists Say

To form this picture, we spoke with leading scientists who know the field.

“Highly competitive and complex grant schemes often have a very unfortunate relation between effort and expected value per participating researcher. In the worst case, the combined time investment of the applicants may exceed the total grant budget.”
Martin Dresler Professor, Donders Institute for Brain, Cognition and Behaviour · Has published repeatedly on science funding
“Ik zou meer geld naar fundamentele wetenschap schuiven. Daar zijn universiteiten uniek in. De start van ieder nieuw geneesmiddel was toch eigenlijk een nieuw inzicht dat uit een van de universiteiten wereldwijd kwam.”
Hans Clevers Physician, biochemist and professor emeritus, Utrecht University · Former president of the KNAW · Former head of R&D at Roche
“Dit systeem maakt dat onderzoekers wellicht minder snel geneigd zijn om aan fundamentele nieuwe dingen te werken, omdat het dan moeilijker is om geld binnen te krijgen.”
Frits Vaandrager Professor of computer science, Radboud University Nijmegen
“Er wordt een prikkel gecreëerd om weinig controversiële voorstellen te honoreren. Dingen die als een beetje risicovol gezien worden, zijn de eerste voorstellen die sneuvelen. Het leidt tot een beetje kokervisie.”
Vincent Baarslag Researcher, Rathenau Institute
“Langjarige financiële continuïteit is essentieel om baanbrekend wetenschappelijk onderzoek te laten renderen en om innovaties naar de markt te brengen. […] Dit wisselvallig beleid leidt tot verspilling van investeringen.”
Stan Gielen Chair of Big Chemistry · Professor emeritus of biophysics, Radboud University · Former chair of NWO
“The scale, depth and scientific rigor of this cohort make it an important resource for understanding the factors that contribute to resilience and exceptional longevity. As one of the most unique datasets of its kind, it has the potential to generate important insights into healthy aging and resilience to neurodegenerative disease. We've already seen firsthand the value of this research in informing scientific discovery, and continued investment in this work could benefit the broader research community for years to come.”
Dr. Fiona Elwood Vice President and Disease Area Stronghold Leader Neurodegeneration at Johnson & Johnson Innovative Medicine.

Why We Do This

The world’s greatest discoveries come from fundamental research: the work of scientists who dare to be curious without knowing in advance where it will lead. Without it there would be no CRISPR-Cas, no mRNA vaccines and no cancer immunotherapy, all Nobel Prize-winning research. The World Wide Web and ASML began this way too. And the multi-billion market for Ozempic and Wegovy started with a question about the venom of a lizard.

10%

Around 10%, or even less: that is the chance that a proposal for fundamental research above €1.5 million is funded, even when it has been rated highly.

Unpredictable work is hard to fund

Researchers depend on their university and on a range of funds. They move from proposal to proposal, year after year. All that writing time is not spent on research, and it slows exactly the work that yields the most.

The system works against fundamental research

Concrete plans with quick results stand a better chance of funding than open, curiosity-driven research. Universities often have to co-fund to secure money from a fund. The system thus pushes researchers towards quick wins, while it should exist precisely for the major breakthroughs. Companies only step in once results are concrete; the long run-up has to come from science itself.

Enough money, but fragmented

The Netherlands and Europe do invest in research, but spread across 27 countries: 94% national, 6% European. In the United States, 96% comes from a single federal budget, supplemented by large philanthropic foundations. The Netherlands has no equivalent. We rank among the world’s best in publications, yet we do not reach the agreed 3% of GDP for research. Draghi and Wennink reach the same conclusion: fundamental research deserves far greater investment, for the future prosperity of the Netherlands and Europe.

What We Do

We help accelerate researchers working on fundamental research whose breakthroughs can change the world. They do the kind of work other scientists and companies can build on, and from which strong solutions for Europe and the European economy can grow. We focus on research that can help people live longer, healthier lives.

We put funding on the table, but we go further: our aim is for research to stand on its own feet and for its value to flow back to science. So that the next breakthrough does not have to start again with a grant application.

Our Approach

Pillar 1

Rigorous research selection through internal due diligence

Pillar 2

Active adoption and acceleration

Pillar 3

Transparent progress and accountability

ANBI Details

Name Lenos Foundation
RSIN 869513849
Contact details
Herenweg 74,
3625 AH, Breukeleveen
Nederland
Policy plan outline Lenos Foundation
Objective The foundation's objective is to promote the public benefit, in particular by stimulating, supporting, and financing scientific research in Europe in the fields of healthcare and life sciences, as well as accelerating the societal impact of such research, and furthermore all that is directly or indirectly related to or may be conducive to the foregoing, in the broadest sense of the word, provided this is exclusively or almost exclusively in the public benefit.
Board roles
Peter Frankhuizen
Treasurer

Gijs Nagel
Chair

Gert Jan Holstege
Secretary
Remuneration policy The members of the board receive no remuneration for their work.

Board

Lenos Foundation maintains a governance structure that follows the guidelines for good governance of charitable organisations.

Gijs Nagel Chair
Gert Jan Holstege Secretary
Peter Frankhuizen Treasurer

Our board members receive no compensation.

Lenos Foundation

We are a non-profit foundation established by the team behind Lenos Equity. Here, we use our proven expertise in due diligence and scaling to support European research.

Get In Touch

Do you have questions about our research projects, want to become a partner, or have a press enquiry? We would be pleased to hear from you.

info@lenosfoundation.eu
Go to the contact page